HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
WEGOVY
®
safely and effectively. See full prescribing information
for WEGOVY.
WEGOVY (semaglutide) injection, for subcutaneous use
Initial U.S. Approval: 2017
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
• In rodents, semaglutide causes thyroid C-cell tumors at clinically
relevant exposures. It is unknown whether WEGOVY causes
thyroid C-cell tumors, including medullary thyroid carcinoma
(MTC), in humans as the human relevance of semaglutide-induced
rodent thyroid C-cell tumors has not been determined (5.1, 13.1).
•
WEGOVY is contraindicated in patients with a personal or
family history of MTC or in patients with Multiple Endocrine
Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding
the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙RECENT MAJOR CHANGES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
Indications and Usage (1) 12/2022
Dosage and Administration (2.1, 2.3) 12/2022
Warnings and Precautions (5.3, 5.6, 5.8) 12/2022
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙INDICATIONS AND USAGE∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist
indicated as an adjunct to a reduced calorie diet and increased physical
activity for chronic weight management in:
• adult patients with an initial body mass index (BMI) of
o 30 kg/m
2
or greater (obesity) or
o 27 kg/m
2
or greater (overweight) in the presence of at least one
weight-related comorbid condition (e.g., hypertension, type 2
diabetes mellitus, or dyslipidemia) (1).
• pediatric patients aged 12 years and older with an initial BMI at the
95th percentile or greater for age and sex (obesity) (1).
Limitations of Use:
• WEGOVY should not be used in combination with other
semaglutide-containing products or any other GLP-1 receptor
agonist (1).
• The safety and efficacy of coadministration with other products for
weight loss have not been established (1).
• WEGOVY has not been studied in patients with a history of
pancreatitis (1).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE AND ADMINISTRATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
• Administer WEGOVY once weekly, on the same day each week, at
any time of day, with or without meals (2.2).
• Inject subcutaneously in the abdomen, thigh or upper arm (2.2).
• In patients with type 2 diabetes, monitor blood glucose prior to
starting and during WEGOVY treatment (2.2).
• Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals,
increase the dose until a dose of 2.4 mg is reached (2.3).
• The maintenance dose of WEGOVY is 2.4 mg once weekly (2.3).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙DOSAGE FORMS AND STRENGTHS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
Injection: pre-filled, single-dose pen that delivers doses of 0.25 mg, 0.5 mg, 1
mg, 1.7 mg or 2.4 mg (3).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
• Personal or family history of medullary thyroid carcinoma or in patients with
Multiple Endocrine Neoplasia syndrome type 2 (4, 5.1).
• Known hypersensitivity to semaglutide or any of the excipients in WEGOVY
(4).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
• Thyroid C-cell Tumors: See Boxed Warning (5.1).
• Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if
pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2).
• Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is
suspected, gallbladder studies and clinical follow-up are indicated (5.3).
• Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may
increase the risk of hypoglycemia, including severe hypoglycemia. Reducing
the dose of insulin secretagogue or insulin may be necessary. Inform all
patients of the risk of hypoglycemia and educate them on the signs and
symptoms of hypoglycemia (5.4, 7.1).
• Acute Kidney Injury: Has occurred. Monitor renal function when initiating or
escalating doses of WEGOVY in patients reporting severe adverse
gastrointestinal reactions or in those with renal impairment reporting severe
adverse gastrointestinal reactions (5.5).
• Hypersensitivity Reactions: Anaphylactic reactions and angioedema have
been reported postmarketing. Discontinue WEGOVY if suspected and
promptly seek medical advice (5.6).
• Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has
been reported in trials with semaglutide. Patients with a history of diabetic
retinopathy should be monitored (5.7).
• Heart Rate Increase: Monitor heart rate at regular intervals (5.8).
• Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts.
Discontinue WEGOVY if symptoms develop (5.9).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ADVERSE REACTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients
aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal
pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation,
hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and
gastroesophageal reflux disease, and nasopharyngitis (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk
Inc., at 1-833-934-6891 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
------------------------------DRUG INTERACTIONS-----------------------------------
WEGOVY delays gastric emptying. May impact absorption of concomitantly
administered oral medications. Use with caution (7.2).
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙USE IN SPECIFIC POPULATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙
• Pregnancy: May cause fetal harm. When pregnancy is recognized,
discontinue WEGOVY (8.1).
• Females and Males of Reproductive Potential: Discontinue WEGOVY at
least 2 months before a planned pregnancy because of the long half-life of
semaglutide (8.3).
See 17 for PATIENT COUNSELING INFORMATION and
Medication Guide.
Reference ID: 5099892